Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReVIVE: Clemastine Fumarate for Myelin Repair in MS
NCT05359653Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Aug 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of clemastine in relapsing-remitting multiple sclerosis (RRMS), sponsored by University of California, San Francisco. Started Aug 2023; status: recruiting.
02
Drugs
clemastine
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05359653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359653.